TY - JOUR
T1 - Proceedings of the first global workshop on breast cancer
T2 - Pathways to the evaluation and clinical development of novel agents for breast cancer
AU - Albain, Kathy S.
AU - Carey, Lisa
AU - Gradishar, William J.
AU - Gralow, Julie R.
AU - Lipton, Allan
AU - Rugo, Hope
AU - Tripathy, Debu
AU - Peck, Susan
AU - Abair, Tristin
AU - Pegram, Mark
N1 - Funding Information:
The workshop was supported by an educational grant from Bristol-Myers Squibb Company, ImClone Systems Incorporated, and sanofi-aventis U.S. The FDA recently approved the halichondrin B analog eribulin mesylate for the treatment of MBC in patients who have received at least two prior chemotherapeutic regimens for advanced disease and who have been treated with prior anthracycline and taxane therapy based on the PFS and OS benefit in the phase III EMBRACE trial. The RANKL-targeted monoclonal antibody denosumab was also recently FDA-approved for SREs in patients with bone metastases from solid tumors.
Funding Information:
Kathy S. Albain has received institutional research support from Merck & Co., Inc.; and has been a consultant or been on an advisory board for Genentech, Inc., Genomic Health, Inc., and Wyeth Pharmaceuticals. Lisa Carey has received institutional research support from Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Genentech, Inc., GlaxoSmithKline, Pfizer Inc., and Wyeth Pharmaceuticals; and has been a consultant or been on an advisory board (through institutional contract) for Bristol-Myers Squibb Company, Genentech, Inc., GlaxoSmithKline, Pfizer Inc., sanofi-aventis U.S., and Wyeth Pharmaceuticals. William J. Gradishar has been a consultant or been on an advisory board for AstraZeneca. Julie R. Gralow has received research funding from Amgen, Genentech, Inc., Novartis Pharmaceuticals Corporation, and Roche Pharmaceuticals. Allan Lipton has received research support from Monogram Biosciences, Novartis Pharmaceuticals Corporation, Oncogene Science; has been a consultant or been on an advisory board for Amgen, Acceleron Pharma, Monogram Bioscience, Novartis Pharmaceuticals Corporation; has served on a Speaker's Bureau for Amgen, Genentech, Inc., and Novartis Pharmaceuticals Corporation; and has given expert testimony for Novartis Pharmaceuticals Corporation. Hope Rugo has received research funding from Abbott Laboratories, Bristol-Myers Squibb Company, GlaxoSmithKline, Genentech, Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., and Roche Pharmaceuticals; and has served on a Speaker's Bureau (no compensation) for Novartis Pharmaceuticals Corporation. Deby Tripathy has been a consultant for BiPar Sciences, Incorporated; and has served on a Speaker's Bureau for Genentech, Inc. Mark Pegram has held a leadership positions/been on a Scientific Advisory Board for Takeda Pharmaceutical Company Limited and Wyeth Pharmaceuticals; has received research funding from sanofi-aventis U.S.; has served as a consultant or been on an advisory board for Amgen, Genentech, Inc./Roche Pharmaceuticals, GlaxoSmithKline, and Prometheus; and has served on a Speaker's Bureau for AstraZeneca, Genentech, Inc., and sanofi-aventis U.S. The remaining authors have no relevant relationships to disclose.
PY - 2010/12
Y1 - 2010/12
N2 - The number of treatment options available to patients with breast cancer is larger and more complex than ever before. This is due in part to increased understanding of breast cancer tumor biology and the signaling pathways involved in tumor development and progression, which drives new areas of breast cancer research and the development of novel agents. Therapies targeting HER2 signaling, angiogenesis, DNA repair, and many other essential cellular processes that are dysregulated in cancer have produced significant improvements in disease outcome, although careful patient selection and toxicity management are required to maximize their therapeutic potential. Multigene assays have added to the ability to predict disease outcome and degree of response to adjuvant chemotherapy, but the application of these assays in the right clinical context is necessary. Unfortunately, despite the use of appropriate and effective local and adjuvant therapies, some patients with early-stage breast cancer will eventually develop metastatic disease. Most of these patients will have received standard therapies in the adjuvant setting and/or will develop resistance to these therapies at some point during treatment. Thus, implementation of novel strategies is necessary to overcome resistance and improve disease outcome. This in turn will require creative clinical trial designs, more efficient accrual, and rapid translation of results into the clinical setting. This summary highlights selected challenges in the current management of breast cancer and discusses expert perspectives, key questions, areas of debate, and future directions.
AB - The number of treatment options available to patients with breast cancer is larger and more complex than ever before. This is due in part to increased understanding of breast cancer tumor biology and the signaling pathways involved in tumor development and progression, which drives new areas of breast cancer research and the development of novel agents. Therapies targeting HER2 signaling, angiogenesis, DNA repair, and many other essential cellular processes that are dysregulated in cancer have produced significant improvements in disease outcome, although careful patient selection and toxicity management are required to maximize their therapeutic potential. Multigene assays have added to the ability to predict disease outcome and degree of response to adjuvant chemotherapy, but the application of these assays in the right clinical context is necessary. Unfortunately, despite the use of appropriate and effective local and adjuvant therapies, some patients with early-stage breast cancer will eventually develop metastatic disease. Most of these patients will have received standard therapies in the adjuvant setting and/or will develop resistance to these therapies at some point during treatment. Thus, implementation of novel strategies is necessary to overcome resistance and improve disease outcome. This in turn will require creative clinical trial designs, more efficient accrual, and rapid translation of results into the clinical setting. This summary highlights selected challenges in the current management of breast cancer and discusses expert perspectives, key questions, areas of debate, and future directions.
UR - http://www.scopus.com/inward/record.url?scp=79952277808&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952277808&partnerID=8YFLogxK
U2 - 10.3816/CBC.2010.n.056
DO - 10.3816/CBC.2010.n.056
M3 - Article
C2 - 21147685
AN - SCOPUS:79952277808
VL - 10
SP - 421
EP - 439
JO - Clinical Breast Cancer
JF - Clinical Breast Cancer
SN - 1526-8209
IS - 6
ER -